Form 4: Prelude Therapeutics Director David Bonita Granted 38,000 Stock Options

David P. Bonita, a Director and 10% owner of Prelude Therapeutics Inc., was granted 38,000 stock options with an exercise price of $1.04, vesting over the next year.

Summary

• David P. Bonita, a Director and 10% owner of Prelude Therapeutics Inc. (PRLD), was granted 38,000 Director Stock Options.
• The transaction date for this grant was June 12, 2025.
• Each option has an exercise price of $1.04.
• The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), contingent on Mr. Bonita's continued service.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Bonita beneficially owns 38,000 derivative securities.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is a positive for aligning management incentives with shareholder interests, but it does not contain significant new operational or financial information to drive a strong sentiment.

Positives

• The grant of 38,000 stock options to Director David P. Bonita aligns his interests with those of shareholders, incentivizing long-term performance.
• The options have a long expiration date of June 11, 2035, providing a significant window for potential value realization.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• The value of the granted stock options is directly tied to the future performance of Prelude Therapeutics Inc.'s common stock, meaning the options could become worthless if the stock price does not exceed the exercise price of $1.04.
• Vesting of the options is contingent upon the reporting person's continued provision of service to the Issuer, posing a risk if service is terminated before vesting.

Future Outlook

The options are set to fully vest upon the earlier of the Issuer's next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), subject to continued service.

Management Comments

• No direct management comments or notable quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing primarily details an insider transaction and does not provide information for broader industry trend analysis.

Comparison to Industry Standards

• This Form 4 filing is specific to an insider equity grant and does not contain information suitable for comparison to industry-wide financial or operational benchmarks.

Related Party Transactions

• The grant of 38,000 Director Stock Options to David P. Bonita, a Director and 10% owner, constitutes a related party transaction as it involves compensation from the Issuer to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align management's long-term interests with those of shareholders, potentially leading to improved company performance.

Next Steps

• The options will vest upon the earlier of Prelude Therapeutics Inc.'s next annual stockholder meeting or June 12, 2026, contingent on Mr. Bonita's continued service.

Key Dates

Keywords

SEC Form 4, Insider Trading, Stock Options, Director Compensation, Prelude Therapeutics, PRLD, Equity Grant, Beneficial Ownership